Aquestive Therapeutics Inc (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercialising differentiated products that meet patients' unmet needs and solve therapeutic problems, announced yesterday its financial results for the first quarter ended 31 March 2019.
The company reported total revenues of USD12.6m in the first quarter 2019 compared to USD23.4m in the first quarter of 2018.
The firm's net loss for the first quarter 2019 was USD14.7m or USD0.59 loss per share.
Keith J Kendall, Aquestive chief executive officer, said, 'We started the year focused on the commercial, regulatory and development milestones that we believe will catalyse our growth and bring value to shareholders. We are progressing as planned across our key initiatives, including the launch of Sympazan, the initiation and execution of a crossover study for Libervant, agreeing with the FDA to move forward with the NDA filing process for that asset, as well as the initiation of the Phase 1 Proof of Concept study for AQST-108.'
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT